Cronos Group completes €57.5 million CanAdelaar acquisition
- Cronos Group acquired all outstanding CanAdelaar shares for a base purchase price of €57.5 million.
- The transaction expands the company's European operating footprint, with the stock trading up at $3.20.
- The company plans to introduce its proprietary genetics and products through the newly acquired Netherlands platform.
Cronos Group (NASDAQ:CRON) completed its acquisition of CanAdelaar for a base purchase price of €57.5 million.
Increased market competition primarily drove the acquired business's earnings decline from €24.2 million during the previous year.
The acquisition establishes a Netherlands operating platform within the Wietexperiment adult-use cannabis pilot.
The final transaction requires additional cash payments equal to half of the acquired business's normalized earnings.
The company plans to introduce its genetics.
The acquired business previously recorded annualized first-half 2026 revenue of €41.6 million and adjusted earnings of €20.1 million.
The purchasing subsidiary waived all contractual closing conditions while the seller provided limited regulatory indemnities.
Frequently asked questions
More from United States
Gray Media reports $972 million Q3 revenue as political advertising surges
VEON boosts 2026 outlook as Q3 revenue grows 17.2% to $1.31 billion
Utz Brands misses Q3 estimates as revenue falls 2.3% and losses widen
Elanco raises 2026 outlook as Q3 revenue grows 11% to $1.265 billion
Algonquin Power reports $57.6 million Q3 net earnings
TDS reveals lower Q3 earnings, adds $250 million buyback
